Prevalence of hepatitis B and C in patients with meningiomas and glioblastoma multiforme

Cabanne,Marc  B.; Ma,Quang  D.; Mecum,Lillian; Jandial,Rahul; Siddiqi,Javed; Chen,Mike  Y.

doi:10.3892/ol.2013.1126

Prevalence of hepatitis B and C in patients with meningiomas and glioblastoma multiforme

Authors:
- Marc B. Cabanne
- Quang D. Ma
- Lillian Mecum
- Rahul Jandial
- Javed Siddiqi
- Mike Y. Chen
View Affiliations

Affiliations: Division of Neurosurgery, Arrowhead Regional Medical Center, Colton, CA 92324, USA, Division of Neurosurgery, City of Hope National Medical Center, MOB 2001J, Duarte, CA 91010, USA
Published online on: January 10, 2013 https://doi.org/10.3892/ol.2013.1126
Pages: 783-786

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prevalence of hepatitis B and C in patients with glioblastoma multiforme or meningiomas has not been described. These infections are known to modulate the activity of the immune system, which potentially influences the development and course of cancer. We hypothesized that chronic hepatitis infection, which activates the immune system, decreases the risk of brain tumors, particularly those that are highly malignant. We performed a retrospective study to examine the prevalence of hepatitis B and C in patients with meningiomas and glioblastomas. The combined prevalence of hepatitis B and C in the USA from 1999‑2008 was 5.7%. The prevalence of hepatitis B and C in patients with meningiomas was 2.4%; while among glioblastoma patients, the prevalence of hepatitis B and C was 1.38%. The odds ratio of having hepatitis B or C with glioblastoma versus meningiomas was 0.56, with a confidence interval of 0.19-1.6 and a P-value of 0.29. Compared with historical controls, the prevalence of hepatitis B and C in meningioma and glioblastoma patients was decreased. However, this difference may be attributed to the retrospective nature of our data and the natural history of hepatitis B and C infections. The prevalence of these viral infections was not statistically different in patients with meningiomas and glioblastomas. This suggests that hepatitis B and C primarily influence slow-growing, benign tumors and more aggressive cancers equally, if at all. To definitively test our hypothesis, future studies in which data are prospectively gathered are likely to be required.

View Figures

View References

1	Dolecek TA, Propp JM, Stroup NE, et al: CBTRUS Statistical Report: Primary Brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 14(suppl 5)2012.PubMed/NCBI
2	McCarthy BJ, Davis FG, Freels S, et al: Factors associated with survival in patients with meningioma. J Neurosurg. 88:831–839. 1998. View Article : Google Scholar : PubMed/NCBI
3	Kasai Y, Takeda S and Takagi H: Pathogenesis of hepatocellular carcinoma: a review from the viewpoint of molecular analysis. Semin Surg Oncol. 12:155–159. 1996. View Article : Google Scholar : PubMed/NCBI
4	Zondervan PE, Wink J, Alers JC, et al: Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J Pathol. 192:207–215. 2000. View Article : Google Scholar
5	Hsia CC, Scudamore CH, Di Bisceglie AM, et al: Molecular and serological aspects of HBsAg-negative hepatitis B virus infections in North America. J Med Virol. 70:20–26. 2003. View Article : Google Scholar : PubMed/NCBI
6	Bréchot C: Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 127:S56–S61. 2004.PubMed/NCBI
7	Everhart JE: Digestive Diseases in the United States: Epidemiology and Impact. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Government Printing Office; Washington, DC: 1994
8	Schoemaker MJ, Swerdlow AJ, Hepworth SJ, et al: History of allergies and risk of glioma in adults. Int J Cancer. 119:2165–2172. 2006. View Article : Google Scholar : PubMed/NCBI
9	Wiemels JL, Wiencke JK, Sison JD, et al: History of allergies among adults with glioma and controls. Int J Cancer. 98:609–615. 2002. View Article : Google Scholar : PubMed/NCBI
10	Wrensch M, Weinberg A, Wiencke J, et al: Does prior infection with varicella-zoster virus influence risk of adult glioma? Am J Epidemiol. 145:594–597. 1997. View Article : Google Scholar : PubMed/NCBI
11	Dempsey WL, Smith AL and Morahan PS: Effect of inapparent murine hepatitis virus infections on macrophages and host resistance. J Leukoc Biol. 39:559–565. 1986.PubMed/NCBI
12	Schindler L, Engler H and Kirchner H: Activation of natural killer cells and induction of interferon after injection of mouse hepatitis virus type 3 in mice. Infect Immun. 35:869–873. 1982.PubMed/NCBI
13	Tamura T, Sakaguchi A, Kai C, et al: Enhanced phagocytic activity of macrohpages in mouse hepatitis virus-infected nude mice. Microbiol Immunol. 24:243–247. 1980. View Article : Google Scholar : PubMed/NCBI
14	Virelizier JL, Virelizier AM and Allison AC: The role of circulating interferon in the modifications of immune responsiveness by mouse hepatitis virus (MHV-3). J Immunol. 117:748–753. 1976.PubMed/NCBI
15	Li LH, DeKoning TF, Nicholas JA, et al: Effect of mouse hepatitis virus infection on combination therapy of P388 leukemia with cyclophosphamide and pyrimidinones. Lab Anim Sci. 37:41–44. 1987.PubMed/NCBI
16	Kawakami Y, Nabeshima S, Furusyo N, et al: Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection. Am J Gastroenterol. 95:227–232. 2000.
17	Morahan PS, Edelson PJ and Gass K: Changes in macrophage ectoenzymes associated with anti-tumor activity. J Immunol. 125:1312–1317. 1980.PubMed/NCBI
18	Inoue M, Kanto T, Miyatake H, et al: Enhanced ability of peripheral invariant natural killer T cells to produce IL-13 in chronic hepatitis C virus infection. J Hepatol. 45:190–196. 2006. View Article : Google Scholar : PubMed/NCBI
19	Li L, Xia Y, Nguyen A, et al: Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol. 162:2477–2487. 1999.PubMed/NCBI
20	Kennedy BC, Maier LM, D’Amico R, et al: Dynamics of central and peripheral immunomodulation in a murine glioma model. BMC Immunol. 10:112009. View Article : Google Scholar : PubMed/NCBI
21	Hao C, Parney IF, Roa WH, et al: Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol. 103:171–178. 2002. View Article : Google Scholar : PubMed/NCBI
22	McQuillian GM, Kruszon-Moran D, Denniston MM, et al: Viral hepatitis. NCHS Data Brief 1–8. 2010